MYP_031456
Basic Information
Trastuzumab
Anticancer
Hormonal / Endocrine Hormone peptide
Immunology Immune modulation Immunomodulatory activity
Therapeutic / Biomedical activity Enzyme replacement therapy
Standard
214 amino acids
C1032H1603N277O335S6
Standard
Sequence
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Physicochemical Analysis
23442.81 Da
7.76
0.99
0.50
0.0046
-0.45
0.58
-0.02
54.43
64.67
0.0981
25900.00
26150.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0249760 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Cricetulus griseus [Animal]
Monoclonal antibody
9606;10029
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Lipidation
Bio-Activity Profile
Anticancer Immunomodulatory Hormone replacement Enzyme replacement
CHO
average 28.5 days
RECORD: Rec_0261614 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Cricetulus griseus [Animal]
Monoclonal antibody
9606;10029
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer Immunomodulatory
CHO
average 28.5 days